ORIC Pharmaceuticals Names Edna Chow Maneval as Senior Vice President of Clinical Development
March 04, 2019 at 08:45 am EST
Share
ORIC Pharmaceuticals announced that Edna Chow Maneval, PhD, has been named Senior Vice President of Clinical Development. Dr. Chow Maneval will serve on the executive leadership team and, together with Chief Medical Officer Pratik Multani, MD, lead clinical development for ORIC. Dr. Chow Maneval brings to ORIC more than 20 years of clinical development experience in oncology. Most recently, she was Senior Vice President of Clinical Development at Ignyta (acquired by Roche in 2018), where she was the clinical lead for entrectinib, a molecularly-targeted therapy for rare cancers affecting adult and pediatric patients. Prior to Ignyta, she was Vice President of Clinical Development of Aragon (acquired by Johnson & Johnson in 2013) and Seragon (acquired by Genentech in 2014), responsible for the apalutamide (ERLEADA) and SERD clinical programs in prostate and breast cancers, respectively. Dr. Chow Maneval's career in drug development started at Pfizer, where she held positions of increasing responsibility within the oncology group, primarily dedicated to the development and approval of sunitinib (SUTENT).
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
ORIC PHARMACEUTICALS, INC. 
